Obesity is a chronic disease characterized by the excessive accumulation of adipose tissue that is harmful to health. Dietary habits modification through a caloric restriction, macronutrient distribution including linoleic and linolenic (n-6:n-3) polyunsaturated fatty acids (PUFAs) ratio, has been suggested for obesity management. It has been proposed that the optimal n-6: n-3 ratio should be between 1:1 and 5:1 to maintain a healthy balance. Purpose: Compare the effect of a diet n6:n3 ratio of polyunsaturated fatty acids with a group supplemented with n-3 PUFA on lipid profile in erythrocyte membrane, biochemical and inflammatory markers in subjects with obesity. Methods: 58 subjects were randomly divided into two groups: fish oil group and the placebo group. Anthropometric and biochemical data were evaluated, cytokine levels was performed using the Bio-PlexPro™ HumanTh17Cytokine Assays (MagPix) panel. The fatty acid profile quantification in the erythrocyte membrane was carried out by gas chromatography. Statistical analysis was performed with Statistical Package for the Social Sciences (SPSS) v.22 software.
A randomized clinical trial was conducted at the Institute of Translational Nutrigenetics and Nutrigenomics of the University of Guadalajara. All participants were recruited through flyers and social media invitations. Sample size was determined according to the mean difference formula for clinical trials. To achieve a statistical power of 80% and an alpha of 5%, a sample size of 19 participants in each study group was required. However, 58 obese individuals who met the selection criteria were randomized in n-3 group or placebo group. Blood sample, height and weight were measured after 8-12 hour fast and wearing light clothes. The nutritional intervention consisted in 20% reduction by the total estimated energy through the Mifflin-St.Jeor formula was calculated, following a 50% to carbohydrates, 20% to proteins and 30% to lipids distribution. All participants received a balanced nutritional plan of omega-6/omega-3 close to 5:1 ratio, according to estimated energy. Additionally, a high omega-3 foods list was proportioned to emphasize their consumption during the study. Fish oil group besides the diet was supplemented with omega 3, the dosage was 2 capsules per day, containing 1.5 g of total omega 3, of which 1000 mg were EPA and 500mg DHA. The omega 3 capsules were obtained from the same batch, and a toxicity analysis was performed to verify the safety or the placebo group (2 capsules per day made from sunflower oil). This study was approved by the Ethics and Biosafety Committee of the Health Sciences Center, University of Guadalajara (Registration number CI-01219) and was carried out according to the Declaration of Helsinki (2013) and all the participants signed a written consent-informed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
58
n-3 supplementation group (1.5g of omega 3)
Placebo group (sunflower oil)
University of Guadalajara
Guadalajara, Jaliscco, Mexico
Erika Martínez-López
Guadalajara, Jalisco, Mexico
The fatty acid profile quantification
All the samples was performed in a Gas Chromatograph (GC) Agilent Technologies, 6850 network system coupled to an injector (Agilent Technologies, 7083 Series) with a column for fatty acids (Durabond, DB-23). flame ionization detector with helium as gas carrier (0.7 cm3 min-1) and a temperature ramp (110 °C - 220 °C).
Time frame: Mean change from baseline (0 Month) to end of treatment at 4th Month
Pro-inflammatory and Anti-inflammatory Cytokines profile in serum
The pro-inflammatory and anti-inflammatory cytokines quantification were using Bio-Plex Pro™ Human cytokine Standard 17-Plex, Group I kit following the supplier's instructions, and the read was immediately by MAGPIX™ analyzer. The 17 cytokine include: IL1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL17A, G-CSF, GM-CSF, INF-γ, MCP-1, MIP1α, TNFα. Units of measure in pg/ml.
Time frame: Mean change from baseline (0 Month) to end of treatment at 4th Month
Changes in Weight
The weight was measured in kilograms on InBody 370
Time frame: At the baseline (0 Month) and 1st month, 2nd month, 3th month and the 4th month
Changes in Body Mass Index (BMI)
Weight and height were be combined to report BMI in kg/m\^2
Time frame: At the baseline (0 Month) and 1st month, 2nd month, 3th month and the 4th month
Changes in Waist Circumference
Waist circumference was measured at the narrowest point between the edge of the inner rib and the iliac crest, with the participant in an abducted and relaxed position, after expiration using a Lufkin Executive® tape.
Time frame: At the baseline (0 Month) and 1st month, 2nd month, 3th month and the 4th month.
Changes in Fat Mass
The Fat Mass was measured in kilograms by electrical bioimpedance on InBody 370.
Time frame: At the baseline (0 Month) and 1st month, 2nd month, 3th month and the 4th month
Changes in Serum Glucose
It was measured in mg/dL using a dry chemistry system in Vitros 350 equipment.
Time frame: At the baseline (0 Month) and 1st month, 2nd month, 3th month and the 4th month
Changes in Serum Insulin
Were determined through Insulin Model ELISA kit following the supplier's instructions.
Time frame: At the baseline (0 Month) and the 4th month
Changes in homeostatic model assessment - insulin resistance (HOMA-IR)
Serum glucose and Insulin levels were be combined to report HOMA-IR calculated as described by Matthews.
Time frame: At the baseline (0 Month) and the 4th month
Changes in Total Cholesterol
It was measured in mg/dL using a dry chemistry system in Vitros 350 equipment.
Time frame: At the baseline (0 Month) and 1st month, 2nd month, 3th month and the 4th month
Changes in High-density lipoprotein (c-HDL)
It was measured in mg/dL using a dry chemistry system in Vitros 350 equipment.
Time frame: At the baseline (0 Month) and 1st month, 2nd month, 3th month and the 4th month
Changes in Low-density lipoprotein (c-LDL)
It was calculated using Friedewald formula
Time frame: At the baseline (0 Month) and 1st month, 2nd month, 3th month and the 4th month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.